Queen Mary University of London is recruiting patients for a cholesterol-lowering drug for patients intolerant to statins.
Reports MedicalXpress, the CLEAR Outcomes study is recruiting 14,000 patients worldwide from 1000 sites located in over 30 countries (including the UK). Studying whether Bempedoic acid reduces the risk for cardiovascular disease, this article focuses on London. Mary Salim, 72 was put on statins post heart attack 15 years ago. However, Ms. Salim wasn’t able to tolerate statins—and she attempted to consume many varieties of the drug.
What is Bempedoic Acid?
It is a drug under development by Esperion Therapeutics for the treatment of hypercholesterolemia. It has thus far been well-tolerated in patients and has shown to be safe and efficacious in lowering bad cholesterol. As of early 2019, its effects on cardiovascular morbidity and mortality have not been determined, but studies are under way.
Lead researcher Dr. Manish Saxena from Queen Mary University of London said, “Statins are effective in lowering bad cholesterol in the body and prevent heart attacks and strokes. Unfortunately, a small number of patients are unable to tolerate statins due to side effects such as muscle aches and pains.”
The actual study is sponsored by Esperion Therapeutics with collaborator Cleveland Clinic. They describe the purpose of the study is to determine if treatment of bempedoic acid (ETC-1002) versus placebo decreases risk of cardiovascular events in patients who are statin intolerant. The study includes 12,600 participants and 1336 research sites.
The UK-based lead researcher is Dr. Manish Saxena from Queen Mary University of London.